Q-omics provides the consensus-scored SLC25A26 profile across patient tissues and cancer cell-line models. SLC25A26 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SLC25A26 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, SLC25A26 RNA expression shows 18,247 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, COAD, and ACC as cancer lineages where SLC25A26 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC25A26 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC25A26 survival associations across molecular data types. SLC25A26 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC25A26 RNA expression–survival associations across cancer types. High SLC25A26 expression shows unfavorable associations in ACC, CESC, LIHC and KICH, but favorable associations in UVM and BRCA. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SLC25A26 RNA expression.
This table summarizes SLC25A26 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC25A26. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC25A26 shows lower tumor expression in THCA, KIRC, LUSC and BRCA and higher tumor expression in COAD and LIHC. The COAD box plot shows higher SLC25A26 RNA expression in tumor versus normal tissue (log2 FC = +0.516, t-test p < 0.001).
This table shows molecular features associated with SLC25A26 in patient tissues and cancer cell lines. In patient samples, SLC25A26 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC25A26 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and UPPER_AERODIGESTIVE_TRACT.
